Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03194646 · ClinicalTrials.gov registry record · Phase 3
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
A Phase 3 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,272
- Enrollment target
NCT03194646 is a Phase 3 study that was terminated before completion, run by Bayer. The registered enrollment target is 1,272 participants.
The verdict
NCT03194646, a Phase 3 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,272 participants
- Enrollment target
Study Summary
The study was performed to assess the efficacy and safety of Vilaprisan in subjects with uterine fibroids compared to standard of care
Interventions
- OTHER Standard of care
- DRUG Vilaprisan (BAY1002670)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,272 participants |
| Start Date | 2017-06-30 |
| Est. Completion | 2024-07-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03194646
The ClinicalTrials.gov registry entry for NCT03194646 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of care is the first listed.
NCT03194646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03194646 about?
NCT03194646 is a clinical study titled "Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids". The study was performed to assess the efficacy and safety of Vilaprisan in subjects with uterine fibroids compared to standard of care
What is the current status of trial NCT03194646?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,272 participants. The study started on 2017-06-30. Estimated completion is 2024-07-11.
What interventions are being tested in trial NCT03194646?
The interventions under investigation include: Standard of care (OTHER), Vilaprisan (BAY1002670) (DRUG).
Who is sponsoring clinical trial NCT03194646?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.